Skip to main content
SRXHSRX Global Inc.Hold4.4·$1.52-4.09%
HoldModerate Confidence
Investment thesis

SRX Global is a sub-$400M micro-cap in the engine's most severe downtrend technical setup, with the weakest possible Piotroski F-Score of 0/9 and no identified trading edge, leaving elevated short interest as the primary open question for a stock already down -95% from its highs.

Thesis pillars

  • Sub Scale Market Cap Not InvestableDeteriorating
  • Severe Downtrend Technical SetupStable
  • Weakest Possible Piotroski ScoreStable
  • +2 more pillars — see the Why tab for full reasoning

Full reasoning →

Open full analysis

SRX Global Inc. (SRXH) Stock Analysis

Recovery setup

HoldVALUE-TRAP 1/5Moderate Confidence

Consumer Defensive · Packaged Foods

Hold if already holding. Not a fresh buy at $1.52, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: top three vendors (85.0%); Market cap $31M below $400M minimum.

SRx Global (formerly Better Choice Company) is a pet health and wellness company selling premium Halo-brand pet food, treats and supplements primarily through e-commerce partners including Amazon and Chewy, alongside brick-and-mortar retail and limited international sales.... Read more

$1.52+14.8% A.UpsideScore 4.4/10#32 of 33 Packaged Foods
QualityF-score0 / 9FCF yield
Stop $1.42Target $1.75(default +15%)A.R:R 0.0:1

Hold if already holding. Not a fresh buy at $1.52, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: top three vendors (85.0%); Market cap $31M below $400M minimum. Chart setup: Death cross but MACD improving, RSI 43. Market cap $31M below $400M minimum. Not in investable universe. Score 4.4/10, moderate confidence.

Passes 5/9 gates (clean insider activity, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: speculative.

10-K grounded · weekly refresh

About SRX Global Inc.

About SRX Global Inc.

SRx Global's continuing operations, conducted through its Halo pet food brand, generated approximately $6.5 million in net sales for the year ended September 30, 2025, sold across e-commerce, brick-and-mortar and international channels. The company's legacy specialty pharmaceutical business, formerly operated under the SRx name, is now reported as a discontinued operation following its bankruptcy, while Halo's more than 100 products are manufactured in the United States through co-manufacturing partners.

SRx Global's Halo brand generates most continuing-operations revenue through e-commerce partner websites such as Amazon, Chewy, Petflow, Thrive Market and Vitacost, driven largely by repeat purchases that reflect brand loyalty, while brick-and-mortar sales run through specialty pet stores and select grocery chains after the company exited direct sales to Petco and Pet Supplies Plus stores in December 2023. International sales, once including Halo Asia, now contribute only a limited and non-material share of revenue following that business's sale. Production relies on co-manufacturing partners including Alphia for dry kibble, Simmons Pet Food and Thai Union Manufacturing for canned wet food, BrightPet Nutrition Group for vegan kibble and freeze-dried treats, and Carnivore Meat Company for freeze-dried food, with third-party logistics provider Fidelitone handling fulfillment from a Wauconda, Illinois warehouse. Competitors include Mars, Incorporated and Nestlé, both of which also own major specialty pet food brands.

Show full overview

SRx Global's supply chain is highly concentrated: the company sourced approximately 85% of its inventory purchases from just three vendors for the year ended September 30, 2025, spanning co-manufacturing relationships for dry kibble, canned wet food, vegan kibble and freeze-dried products. That concentration compounds a quality-control risk the 10-K flags directly — if any sourced raw material, such as certified cage-free chicken or wild-caught salmon, is adulterated or fails to meet specifications, it could significantly impair the company's ability to source manufactured products and materially affect its financial condition, leaving little room to absorb a single vendor's disruption given how few alternatives are named.

See also: Consumer Defensive · Packaged Foods

From SRX Global Inc.'s most recent 10-K filing, extracted July 19, 2026.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-07-28

Thesis

Rewards
No bull case signals
Risks
Concentration risk — Supplier: top three vendors (85.0%)
Market cap $31M below $400M minimum

Key Metrics

P/E (TTM)
P/E (Fwd)
Mkt Cap$31M
EV/EBITDA
Profit Mgn0.0%
ROE
Rev Growth
Beta
DividendNone
Rating analysts7

Quality Signals

Piotroski F0/9

Concentration Risks(10-K Item 1A)

  • HIGHSuppliertop three vendors85%
    10-K Item 1: 'We sourced approximately 85% of its inventory purchases from three vendors for the year ended September 30, 2025.'

Material Events(8-K, last 90d)

  • 2026-06-24Item 3.01HIGH
    NYSE American notified the company of noncompliance with continued listing standards due to sustained low share price (closed below $0.10 on June 23, 2026) and halted trading pending a reverse stock split intended to regain compliance.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

2 floor-breakers

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Gross Margin
0.0
Operating Margin
0.0
Net Margin
0.0
Piotroski F
0.0
Moat
4.5
No competitive moatWeak Piotroski F-Score: 0/9Quality concerns

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Volume
0.0
Obv
1.0
Ma Position
1.0
Rsi
4.5
Macd
7.5
Volume distribution (falling OBV)Below 200-MA, MA slope -18.9%/30d — confirmed downtrend
GatesMomentum 2.8<4.5Death cross (50MA < 200MA)A.R:R UPSIDE_EXHAUSTED (upside=0.0%)8K FLAG 3.01Insider activity: OKNEWS EVENTS NONE RECENTEARNINGS PROXIMITY NO DATESEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRecoverySuitability: Speculative
RSI
43 · Neutral
20D MA 50D MA 200D MADEATH CROSSSupport $0.94Resistance $5.31

Price Targets

$1
$2
A.R:R0.0:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Market cap $31M below $400M minimum
! momentum at 2.8 (below the engine's 4.5 threshold)
! Death cross — 50-day MA below 200-day MA

Earnings

We could not retrieve earnings history for SRXH.
The company may be recently listed, pre-revenue, or its beat/miss record wasn't available from our source this run. Earnings signals feed the Growth and Catalyst score dimensions — absence here doesn't affect other dimensions.

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is SRXH stock a buy right now?

Hold if already holding. Not a fresh buy at $1.52, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: top three vendors (85.0%); Market cap $31M below $400M minimum. Chart setup: Death cross but MACD improving, RSI 43. Market cap $31M below $400M minimum. Not in investable universe. Target $1.75 (+15.1%), stop $1.42 (−7.0%), A.R:R 0.0:1. Score 4.4/10, moderate confidence.

What is the SRXH stock price target?

Take-profit target: $1.75 (+14.8% upside). Target $1.75 (+15.1%), stop $1.42 (−7.0%), A.R:R 0.0:1. Stop-loss: $1.42.

What are the risks of investing in SRXH?

Concentration risk — Supplier: top three vendors (85.0%); Market cap $31M below $400M minimum.

Is SRXH overvalued or undervalued?

SRX Global Inc. trades at a P/E of N/A (forward N/A). TrendMatrix value score: 5.0/10. Verdict: Hold.

What do analysts say about SRXH?

7 analysts cover SRXH with a consensus score of 4.1/5.

What does SRX Global Inc. do?SRx Global (formerly Better Choice Company) is a pet health and wellness company selling premium Halo-brand pet food,...

SRx Global (formerly Better Choice Company) is a pet health and wellness company selling premium Halo-brand pet food, treats and supplements primarily through e-commerce partners including Amazon and Chewy, alongside brick-and-mortar retail and limited international sales. Continuing operations generated approximately $6.5 million in net sales for the year ended September 30, 2025, while the company's legacy specialty pharmaceutical business, conducted under the SRx name, is reported as a discontinued operation following its bankruptcy and wind-down.

Home Stocks SRXH

Latest news

Latest News

Benzinga12d ago
Benzinga14d ago
Benzinga18d ago
Benzinga19d ago
Benzinga19d ago
Benzinga20d ago
Benzinga20d ago
Benzinga20d ago
Benzinga20d ago
Benzinga21d ago
Benzinga26d ago